U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13N2O3.Na
Molecular Weight 220.2012
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHARBITAL SODIUM

SMILES

CCC1(CC)C(=NC(=O)N(C)C1=O)[O-].[Na+]

InChI

InChIKey=RIJRFNRKNTXEGB-UHFFFAOYSA-M
InChI=1S/C9H14N2O3.Na/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13;/h4-5H2,1-3H3,(H,10,12,14);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C9H14N2O3
Molecular Weight 198.2194
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Methbarbital is a barbiturate anticonvulsant, discovered by Merck in 1905. It was introduced to market for treatment of epolepsy by Abbott in 1952, and discontinued in 1990.

Originator

Curator's Comment:: # Merck

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
GEMONIL

Approved Use

Long-acting barbiturate that is demethylated to barbital in the liver; has broad-spectrum anticonvulsant action, but used mainly to treat myoclonic spasms in infants.
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Effects of barbiturates on human platelet aggregation differ depending on their chemical structures.
2003 Aug
Evaluation of pyridine-3-carboxylic acid as a drug carrier by utilizing multivariate methods, structure property correlations, and pattern recognition techniques.
2004
A categorical structure-activity relationship analysis of the developmental toxicity of antithyroid drugs.
2009
Monitoring antiepileptic drugs: a level-headed approach.
2009 Jun
Patents

Patents

Sample Use Guides

Metharbital is administered orally. Effective dose, causing a reduction in seizure score by 225, is 110 mg.
Route of Administration: Oral
In Vitro Use Guide
The binding of [3H]DHP (dihydropicrotoainin) to rat brain membrane fragments was measured by a centrifugation assay. Assay condition involved incubating 1-3 mg of protein at 0° for 15 min with 63 nM [3H]DHP with or without a given concentration of barbiturate in a total incubation medium of 2 ml. Following incubation, the vials were centrifuged, supernatant discarded, pellets rapidly rinsed, solubilized and prepared for counting as previously described (26) . Specific binding was obtained by subtracting from the total radioactivity in the pellet the background, i .e . the amount not displaced by high concentrations (0.1 mM) of unlabeled DHP. Metharbital inhibits binding of [3H]DHP to GABAA receptor with IC50 of 10 uM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:10:57 UTC 2021
Edited
by admin
on Sat Jun 26 04:10:57 UTC 2021
Record UNII
359HKV5H10
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHARBITAL SODIUM
Common Name English
PYRIMIDINETRIONE, 5,5-DIETHYL-1-METHYL-, SODIUM SALT
Systematic Name English
BARBITURIC ACID, 5,5-DIETHYL-1-METHYL-, SODIUM SALT
Common Name English
Code System Code Type Description
PUBCHEM
14148198
Created by admin on Sat Jun 26 04:10:57 UTC 2021 , Edited by admin on Sat Jun 26 04:10:57 UTC 2021
PRIMARY
FDA UNII
359HKV5H10
Created by admin on Sat Jun 26 04:10:57 UTC 2021 , Edited by admin on Sat Jun 26 04:10:57 UTC 2021
PRIMARY
CAS
35107-70-1
Created by admin on Sat Jun 26 04:10:57 UTC 2021 , Edited by admin on Sat Jun 26 04:10:57 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY